Moxifloxacin as an Alternative to Ethambutol in Tuberculosis Treatment

Current Guideline Recommendations

The American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America suggest using moxifloxacin instead of ethambutol only in specific situations, particularly for isoniazid-resistant TB, but do not recommend wholesale replacement of ethambutol with moxifloxacin in standard TB treatment regimens 1, 2
The American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America guidelines suggest including ethambutol in MDR-TB regimens only when more effective drugs cannot be assembled to achieve a total of five effective drugs in the regimen (conditional recommendation) 3, 4
The American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America guidelines strongly recommend including a later-generation fluoroquinolone (levofloxacin or moxifloxacin) in MDR-TB treatment regimens 2

For isoniazid-resistant TB specifically, guidelines suggest adding a later-generation fluoroquinolone to a 6-month regimen of daily rifampin, ethambutol, and pyrazinamide (conditional recommendation) 1
The World Health Organization MDR-TB drug classification prioritizes fluoroquinolones (levofloxacin/moxifloxacin) as Group A (highest priority drugs), while ethambutol is in Group C (lower priority) 5

For patients with isoniazid-resistant TB, guidelines specifically suggest adding a later-generation fluoroquinolone to rifampin, ethambutol, and pyrazinamide for 6 months 1
In the shorter all-oral bedaquiline-containing regimen for MDR/RR-TB, both moxifloxacin and ethambutol are included, not as alternatives but as complementary drugs 5

Ethambutol is associated with serious adverse events in approximately 0.5% of patients, primarily ocular toxicity 3
When ethambutol is used, patients should be monitored monthly for signs of ocular toxicity 3

For isoniazid-resistant TB, add a later-generation fluoroquinolone (moxifloxacin or levofloxacin) to rifampin, ethambutol, and pyrazinamide 1
For MDR/RR-TB, follow WHO classification - prioritize Group A drugs (including moxifloxacin/levofloxacin) over Group C drugs (including ethambutol) 5
Include ethambutol only when more effective drugs cannot be assembled to achieve a total of five effective drugs 3

Drug susceptibility testing should guide therapy whenever possible 1, 6
The cross-resistance between fluoroquinolones is not complete - 81% of M. tuberculosis isolates resistant to ofloxacin were also resistant to moxifloxacin in European data 1
When ethambutol is used, some experts recommend higher dosing (25 mg/kg) for increased efficacy, though this carries slightly greater risk of ocular toxicity 3
All patients receiving ethambutol should be monitored for visual impairment; if detected, ethambutol should be discontinued 3